Uncovering the basis and implications of lineage plasticity in breast cancer
揭示乳腺癌谱系可塑性的基础和影响
基本信息
- 批准号:10357013
- 负责人:
- 金额:$ 37.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAdjuvant ChemotherapyAttenuatedAutomobile DrivingBasal CellBiologicalBreast Cancer CellBreast CarcinomaCellsCessation of lifeChromatinClinicalCoupledCyclic AMP-Dependent Protein KinasesDataDisease ProgressionEventGTP-Binding Protein alpha Subunits, GsGene Expression ProfilingGenesGeneticGenetically Engineered MouseHabitatsHeterogeneityKnock-in MouseLabelMalignant NeoplasmsMetastatic toModelingMouse Mammary Tumor VirusMutationNeoplasm MetastasisPatternPopulationPrimary NeoplasmProcessPublishingRecurrenceRegimenRelapseResistance developmentRoleSOX4 geneTestingTherapeutic UsesTreatment ProtocolsTumor-Associated ProcessWorkbasecancer cellchemotherapycombinatorialconventional therapygenetic evolutiongenome-widein vivoinsightmalignant breast neoplasmmolecular subtypesneoplastic cellnovelnovel strategiesresponsetraittranscriptometreatment responsetumortumor growthtumor heterogeneitytumor initiationtumor microenvironmenttumor progressiontumorigenesis
项目摘要
Tumorigenesis involves the accumulation of genetic aberrations, leading to the emergence of
distinct clonal subpopulations. Studies that have tracked the evolution of genetic events within
and between these clonal populations have provided deep insights into the process of
tumorigenesis and response to therapy. Despite these advances, the process of metastasis,
which is responsible for over 90% of cancer-related deaths, remains poorly understood. The
majority of studies that compare genetic aberrations between the primary tumor and metastases
find few alterations that are unique to the metastatic clone. Indeed, there are no known
recurrent genetic drivers of metastasis. In contrast to primary tumor initiation and establishment,
my own future research directions hypothesize that the process of metastasis does not rely on
the further acquisition of novel genetic alterations beyond those needed to form primary tumor
cells, but is instead driven by alterations to the chromatin landscape, presenting itself in the form
of cellular plasticity and a reprogrammed cell state. We have uncovered evidence of a luminal-
to-basal transition (LBT) in breast cancers of the luminal B molecular subtype. The LBT is
essential for tumor progression as tumors that do not exhibit this plasticity show attenuated
metastatic ability and are more sensitive to chemotherapy. Based on these data we hypothesize
that the acquisition of tumor cell plasticity that allows breast cancer cells to stray from their
lineage-of-origin is an essential first step to initiating the metastatic cascade and disease
progression. This increased plasticity likely propels cells into a state that is highly adaptive to
new habitats and responsive to interactions with components of the tumor microenvironment, all
of which are critical to the process of metastasis. We propose to test this by elucidating the
effects of the LBT in luminal B breast cancers by assessing the stability of the cells that undergo
the transition, their tumor-initiating capacity and metastatic potential (aim 1). We will further
uncover the mechanisms driving the transition by studying the role of Sox4 in the emergence of
the basal cells of luminal origin, tracking its expression and determining its genome-wide
occupancy to reveal changes to its target gene repertoire during metastatic progression (aim 2).
We then propose to test the principle of tumor differentiation as a potential adjuvant to
chemotherapy by either combinatorial activation of Gαs R201C/fl and chemotherapy administration,
or by sequential activation of Gαs R201C/fl followed by chemotherapy administration.
肿瘤发生涉及遗传畸变的积累,导致出现
不同的克隆亚群。追踪遗传事件进化的研究
这些克隆群体之间的关系提供了对克隆过程的深刻见解
肿瘤发生和对治疗的反应。尽管取得了这些进展,但转移过程
90%以上的癌症相关死亡是由这种疾病造成的,但人们对其仍知之甚少。这
大多数研究比较原发肿瘤和转移瘤之间的遗传畸变
发现转移克隆特有的一些改变。确实,目前还没有已知的
转移的复发性遗传驱动因素。与原发性肿瘤的发生和建立相反,
我自己未来的研究方向假设转移过程不依赖于
进一步获得超出形成原发肿瘤所需的新基因改变
细胞,而是由染色质景观的改变驱动,以以下形式呈现:
细胞可塑性和重新编程的细胞状态。我们发现了发光体的证据——
管腔 B 分子亚型乳腺癌中的基底细胞转变 (LBT)。小比特是
对于肿瘤进展至关重要,因为不表现出这种可塑性的肿瘤会减弱
转移能力强,对化疗更敏感。根据这些数据我们假设
肿瘤细胞可塑性的获得使乳腺癌细胞偏离了它们的定位
起源谱系是启动转移级联和疾病的重要第一步
进展。这种可塑性的增加可能会促使细胞进入一种高度适应的状态
新的栖息地以及对与肿瘤微环境成分的相互作用做出反应,所有这些
其中对于转移过程至关重要。我们建议通过阐明来测试这一点
通过评估经历过 LBT 的细胞的稳定性,研究 LBT 对管腔 B 型乳腺癌的影响
转变、肿瘤启动能力和转移潜力(目标 1)。我们将进一步
通过研究 Sox4 在出现的过程中的作用来揭示驱动转变的机制
腔起源的基底细胞,跟踪其表达并确定其全基因组
占用率以揭示其靶基因库在转移进展过程中的变化(目标 2)。
然后,我们建议测试肿瘤分化的原理作为潜在的佐剂
通过 Gαs R201C/fl 的组合激活和化疗给药进行化疗,
或依次激活 Gαs R201C/fl,然后进行化疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Todd W Miller其他文献
Todd W Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Todd W Miller', 18)}}的其他基金
A precision medicine basis for estrogen therapy for advanced breast cancer
晚期乳腺癌雌激素治疗的精准医学基础
- 批准号:
10930779 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
Uncovering the basis and implications of lineage plasticity in breast cancer
揭示乳腺癌谱系可塑性的基础和影响
- 批准号:
10544736 - 财政年份:2022
- 资助金额:
$ 37.95万 - 项目类别:
Therapeutically leveraging metabolic vulnerabilities in breast cancer
利用乳腺癌代谢脆弱性进行治疗
- 批准号:
10818782 - 财政年份:2022
- 资助金额:
$ 37.95万 - 项目类别:
Therapeutically leveraging metabolic vulnerabilities in breast cancer
利用乳腺癌代谢脆弱性进行治疗
- 批准号:
10659058 - 财政年份:2022
- 资助金额:
$ 37.95万 - 项目类别:
Uncovering the basis and implications of lineage plasticity in breast cancer
揭示乳腺癌谱系可塑性的基础和影响
- 批准号:
10907306 - 财政年份:2022
- 资助金额:
$ 37.95万 - 项目类别:
Therapeutically leveraging metabolic vulnerabilities in breast cancer
利用乳腺癌代谢脆弱性进行治疗
- 批准号:
10908068 - 财政年份:2022
- 资助金额:
$ 37.95万 - 项目类别:
Timing is everything: applications in precision oncology for ER+ breast cancer
时机就是一切:ER 乳腺癌精准肿瘤学中的应用
- 批准号:
9761285 - 财政年份:2017
- 资助金额:
$ 37.95万 - 项目类别:
Timing is everything: applications in precision oncology for ER+ breast cancer
时机就是一切:ER 乳腺癌精准肿瘤学中的应用
- 批准号:
9383150 - 财政年份:2017
- 资助金额:
$ 37.95万 - 项目类别:
A precision medicine basis for estrogen therapy for advanced breast cancer
晚期乳腺癌雌激素治疗的精准医学基础
- 批准号:
9311512 - 财政年份:2017
- 资助金额:
$ 37.95万 - 项目类别:
Timing is everything: applications in precision oncology for ER+ breast cancer
时机就是一切:ER 乳腺癌精准肿瘤学中的应用
- 批准号:
10228617 - 财政年份:2017
- 资助金额:
$ 37.95万 - 项目类别:
相似海外基金
3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
- 批准号:
10556192 - 财政年份:2023
- 资助金额:
$ 37.95万 - 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
- 批准号:
10315227 - 财政年份:2021
- 资助金额:
$ 37.95万 - 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
- 批准号:
443988 - 财政年份:2021
- 资助金额:
$ 37.95万 - 项目类别:
Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
- 批准号:
20K09011 - 财政年份:2020
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
- 批准号:
19K09130 - 财政年份:2019
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
- 批准号:
19K18225 - 财政年份:2019
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
- 批准号:
18K16337 - 财政年份:2018
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
- 批准号:
10005254 - 财政年份:2018
- 资助金额:
$ 37.95万 - 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
- 批准号:
9763320 - 财政年份:2018
- 资助金额:
$ 37.95万 - 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
- 批准号:
18K07341 - 财政年份:2018
- 资助金额:
$ 37.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




